Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-B ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo

Jong Min Baek, Ju Young Kim, Youngeun Jung, Seong Hee Moon, Min Kyu Choi, Seong Hwan Kim, Myeung Su Lee, Ikyon Kim, Jaemin Oh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Osteopenic diseases, such as osteoporosis, are characterized by progressive and excessive bone resorption mediated by enhanced receptor activator of nuclear factor-κB ligand (RANKL) signaling. Therefore, downregulation of RANKL downstream signals may be a valuable approach for the treatment of bone loss-associated disorders. In this study, we investigated the effects of the naphthohydroquinone mollugin on osteoclastogenesis and its function in vitro and in vivo. Mollugin efficiently suppressed RANKL-induced osteoclast differentiation of bone marrow macrophages (BMMs) and bone resorbing activity of mature osteoclasts by inhibiting RANKL-induced c-Fos and NFATc1 expression. Mollugin reduced the phosphorylation of signaling pathways activated in the early stages of osteoclast differentiation, including the MAP kinase, Akt, and GSK3β and inhibited the expression of different genes associated with osteoclastogenesis, such as OSCAR, TRAP, DC-STAMP, OC-STAMP, integrin αν, integrin β3, cathepsin K, and ICAM-1. Furthermore, mice treated with mollugin showed significant restoration of lipopolysaccharide (LPS)-induced bone loss as indicated by micro-CT and histological analysis of femurs. Consequently, these results suggested that mollugin could be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalPhytomedicine
Volume22
Issue number1
DOIs
Publication statusPublished - 2015 Feb 3

Fingerprint

Cytoplasmic and Nuclear Receptors
Osteogenesis
Lipopolysaccharides
Ligands
Bone and Bones
Osteoclasts
Integrins
Osteoporosis
Cathepsin K
Periodontitis
Intercellular Adhesion Molecule-1
Bone Resorption
Femur
Rheumatoid Arthritis
Phosphotransferases
Down-Regulation
Bone Marrow
Macrophages
Phosphorylation
rubimaillin

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine

Cite this

Baek, Jong Min ; Kim, Ju Young ; Jung, Youngeun ; Moon, Seong Hee ; Choi, Min Kyu ; Kim, Seong Hwan ; Lee, Myeung Su ; Kim, Ikyon ; Oh, Jaemin. / Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-B ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo. In: Phytomedicine. 2015 ; Vol. 22, No. 1. pp. 27-35.
@article{ad7cd582103541658247254921aa0154,
title = "Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-B ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo",
abstract = "Osteopenic diseases, such as osteoporosis, are characterized by progressive and excessive bone resorption mediated by enhanced receptor activator of nuclear factor-κB ligand (RANKL) signaling. Therefore, downregulation of RANKL downstream signals may be a valuable approach for the treatment of bone loss-associated disorders. In this study, we investigated the effects of the naphthohydroquinone mollugin on osteoclastogenesis and its function in vitro and in vivo. Mollugin efficiently suppressed RANKL-induced osteoclast differentiation of bone marrow macrophages (BMMs) and bone resorbing activity of mature osteoclasts by inhibiting RANKL-induced c-Fos and NFATc1 expression. Mollugin reduced the phosphorylation of signaling pathways activated in the early stages of osteoclast differentiation, including the MAP kinase, Akt, and GSK3β and inhibited the expression of different genes associated with osteoclastogenesis, such as OSCAR, TRAP, DC-STAMP, OC-STAMP, integrin αν, integrin β3, cathepsin K, and ICAM-1. Furthermore, mice treated with mollugin showed significant restoration of lipopolysaccharide (LPS)-induced bone loss as indicated by micro-CT and histological analysis of femurs. Consequently, these results suggested that mollugin could be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis.",
author = "Baek, {Jong Min} and Kim, {Ju Young} and Youngeun Jung and Moon, {Seong Hee} and Choi, {Min Kyu} and Kim, {Seong Hwan} and Lee, {Myeung Su} and Ikyon Kim and Jaemin Oh",
year = "2015",
month = "2",
day = "3",
doi = "10.1016/j.phymed.2014.10.008",
language = "English",
volume = "22",
pages = "27--35",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",
number = "1",

}

Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-B ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo. / Baek, Jong Min; Kim, Ju Young; Jung, Youngeun; Moon, Seong Hee; Choi, Min Kyu; Kim, Seong Hwan; Lee, Myeung Su; Kim, Ikyon; Oh, Jaemin.

In: Phytomedicine, Vol. 22, No. 1, 03.02.2015, p. 27-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-B ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo

AU - Baek, Jong Min

AU - Kim, Ju Young

AU - Jung, Youngeun

AU - Moon, Seong Hee

AU - Choi, Min Kyu

AU - Kim, Seong Hwan

AU - Lee, Myeung Su

AU - Kim, Ikyon

AU - Oh, Jaemin

PY - 2015/2/3

Y1 - 2015/2/3

N2 - Osteopenic diseases, such as osteoporosis, are characterized by progressive and excessive bone resorption mediated by enhanced receptor activator of nuclear factor-κB ligand (RANKL) signaling. Therefore, downregulation of RANKL downstream signals may be a valuable approach for the treatment of bone loss-associated disorders. In this study, we investigated the effects of the naphthohydroquinone mollugin on osteoclastogenesis and its function in vitro and in vivo. Mollugin efficiently suppressed RANKL-induced osteoclast differentiation of bone marrow macrophages (BMMs) and bone resorbing activity of mature osteoclasts by inhibiting RANKL-induced c-Fos and NFATc1 expression. Mollugin reduced the phosphorylation of signaling pathways activated in the early stages of osteoclast differentiation, including the MAP kinase, Akt, and GSK3β and inhibited the expression of different genes associated with osteoclastogenesis, such as OSCAR, TRAP, DC-STAMP, OC-STAMP, integrin αν, integrin β3, cathepsin K, and ICAM-1. Furthermore, mice treated with mollugin showed significant restoration of lipopolysaccharide (LPS)-induced bone loss as indicated by micro-CT and histological analysis of femurs. Consequently, these results suggested that mollugin could be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis.

AB - Osteopenic diseases, such as osteoporosis, are characterized by progressive and excessive bone resorption mediated by enhanced receptor activator of nuclear factor-κB ligand (RANKL) signaling. Therefore, downregulation of RANKL downstream signals may be a valuable approach for the treatment of bone loss-associated disorders. In this study, we investigated the effects of the naphthohydroquinone mollugin on osteoclastogenesis and its function in vitro and in vivo. Mollugin efficiently suppressed RANKL-induced osteoclast differentiation of bone marrow macrophages (BMMs) and bone resorbing activity of mature osteoclasts by inhibiting RANKL-induced c-Fos and NFATc1 expression. Mollugin reduced the phosphorylation of signaling pathways activated in the early stages of osteoclast differentiation, including the MAP kinase, Akt, and GSK3β and inhibited the expression of different genes associated with osteoclastogenesis, such as OSCAR, TRAP, DC-STAMP, OC-STAMP, integrin αν, integrin β3, cathepsin K, and ICAM-1. Furthermore, mice treated with mollugin showed significant restoration of lipopolysaccharide (LPS)-induced bone loss as indicated by micro-CT and histological analysis of femurs. Consequently, these results suggested that mollugin could be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis.

UR - http://www.scopus.com/inward/record.url?scp=84918526065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918526065&partnerID=8YFLogxK

U2 - 10.1016/j.phymed.2014.10.008

DO - 10.1016/j.phymed.2014.10.008

M3 - Article

VL - 22

SP - 27

EP - 35

JO - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

IS - 1

ER -